Planet Green Holdings Corp. (PLAG) · Nov 18, 2026 · Material agreement
RMB1.55M technology transfer — RMB465,000 + RMB1,007,500 + RMB77,500 staged payments
Planet Green’s agreement adds a registered lactoferrin chewable-tablet platform, but the deal creates no immediate revenue and still requires transfer approval.
Planet Green is still a small, cash-constrained food and health-products operator: its current businesses are tea products and online advertising, while management has only recently begun commercial operations around lactoferrin and chewable immune tablets. The latest quarter showed $9.6 million of nine-month revenue but a $617,000 operating loss, and the company warned that its ability to continue depends on executing its plan and securing additional funding.
The agreement advances the company’s stated lactoferrin strategy with a real product asset. Taihe Bio receives the formula, manufacturing process, technical materials, registration materials and related production and sales rights for a bovine-colostrum, vitamin-C and lactoferrin chewable tablet. The total consideration is RMB1.55 million, paid in three stages rather than entirely upfront. 〔0〕 〔1〕 〔2〕
This is a platform acquisition, not a revenue event yet. The company still must complete pilot production, produce three qualified batches, pass stability testing and obtain the domestic health-food acceptance and registration transfer. The agreement gives Planet Green up to 120 working days to process qualified samples after receiving complete materials, while the acceptance process can extend for up to a year. 〔3〕
| Current figure | Comparison 1 | Comparison 2 | |
|---|---|---|---|
| Technology-transfer consideration (Agreement payment terms) | RMB1.55M | ||
| First installment (Agreement payment terms) | RMB465,000 | ||
| Nine-month revenue (Q3 2026 10-Q — Statements of Operations) | $9.58M | $67,270 | |
| Nine-month operating loss (Q3 2026 10-Q — Statements of Operations) | $617,433 | $(3.72M) | |
| Cash (Q3 2026 10-Q — Balance Sheets) | $356,476 | $15,751 |
The staged structure limits immediate cash exposure, but execution risk is meaningful. The initial payment is modest relative to the total commitment, and Planet Green can defer installments if technical materials or the registration certificate are incomplete. But the company’s cash balance was only $356,476 at September 30, 2026, and management disclosed substantial doubt about its ability to continue as a going concern, so even a modest product launch may compete with working-capital and funding needs.
Bottom line: This is a modestly positive strategic step because it gives Planet Green a concrete lactoferrin product and a path into immune-health supplements. It does not yet change the earnings story: regulatory transfer, manufacturing qualification and commercialization still have to happen before the asset can produce revenue.
Health Food Acceptance Notice and registration transfer
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!